Review Article

Systemic and Nonrenal Adverse Effects Occurring in Renal Transplant Patients Treated with mTOR Inhibitors

Gianluigi Zaza,1 Paola Tomei,1 Paolo Ria,1 Simona Granata,1 Luigino Boschiero,2 and Antonio Lupo1

1 Renal Unit, Department of Medicine, University Hospital of Verona, Piazzale Stefani 1, 37126 Verona, Italy
2 First Surgical Clinic, Kidney Transplantation Center, University Hospital of Verona, Piazzale Stefani 1, 37126 Verona, Italy

Correspondence should be addressed to Gianluigi Zaza; gianluigi.zaza@univr.it

Received 31 January 2013; Revised 8 July 2013; Accepted 4 August 2013

Academic Editor: Phil Mason

Copyright © 2013 Gianluigi Zaza et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The mammalian target of rapamycin inhibitors (mTOR-I), sirolimus and everolimus, are immunosuppressive drugs largely used in renal transplantation. The main mechanism of action of these drugs is the inhibition of the mammalian target of rapamycin (mTOR), a regulatory protein kinase involved in lymphocyte proliferation. Additionally, the inhibition of the crosstalk among mTORC1, mTORC2, and PI3K confers the antineoplastic activities of these drugs. Because of their specific pharmacological characteristics and their relative lack of nephrotoxicity, these inhibitors are valid option to calcineurine inhibitors (CNIs) for maintenance immunosuppression in renal transplant recipients with chronic allograft nephropathy. However, as other immunosuppressive drugs, mTOR-I may induce the development of several adverse effects that need to be early recognized and treated to avoid severe illness in renal transplant patients. In particular, mTOR-I may induce systemic nonnephrological side effects including pulmonary toxicity, hematological disorders, dysmetabolism, lymphedema, stomatitis, cutaneous adverse effects, and fertility/gonad toxicity. Although most of the adverse effects are dose related, it is extremely important for clinicians to early recognize them in order to reduce dosage or discontinue mTOR-I treatment avoiding the onset and development of severe clinical complications.

1. Role and Biological Function of mTOR Inhibitors (mTOR-I)

The mammalian target of rapamycin inhibitors (mTOR-I), sirolimus and everolimus, are agents with many immunosuppressive and anti-cancer properties [1].

The main mechanism of action of these drugs is the inhibition of mammalian target of rapamycin (mTOR). mTOR is a regulatory protein kinase involved in lymphocyte proliferation, developmental processes such as neurologic and muscle generation, and tumor cell growth. Sirolimus (SRL; Rapamune, Wyeth Pharmaceuticals, New York City, NY, USA) was the first mTOR inhibitor (mTOR-I) approved for use in renal transplant recipients. It binds to the immunophilin FK binding protein-12 (FKBP-12). Everolimus (EVR), marketed as Certican, was approved lately, and it is structurally similar to SLR except for the addition of an extra hydroxyethyl group at position 40 [2]. Whereas the Tacrolimus (TAC)/FKBP-12 complex inhibits calcineurin-induced transcription of interleukin-2 (IL-2), the SRL/FKBP-12 and EVR/FKBP-12 complexes both bind directly to mTOR, halting T-cell progression from the G1 to the S phase of cell cycle, leading to inhibition of IL-2-induced protein synthesis and cellular proliferation [3].

Because of their specific pharmacological characteristics, mTOR-I are highly effective in renal transplantation, and thanks to their relative lack of nephrotoxicity, these inhibitors are a valid option to calcineurin inhibitors (CNIs) for maintenance of immune suppression in renal transplant recipients with chronic allograft nephropathy [4–6]. However, as reported by recent studies [7,8], it seems clear that time and drug dosage may have a primary role in the development of drug-related adverse effects and clinical complications.

Additionally, the inhibition of the crosstalk among mTORC1, mTORC2, and phosphatidylinositol-3 kinase (PI3K) confers the antineoplastic activities of these drugs [9]. EVR received Food and Drug Administration (FDA) approval in 2009 for renal cancer carcinoma (RCC) and
successively for tuberous sclerosis and pancreatic neuroendocrine tumors [10, 11]. The anticancer efficacy of mTOR-I seems to be limited to their cytostatic and no cytotoxic activities, so the clinical effect is stabilization rather than regression. Therefore these drugs are extremely useful for the immunosuppressive treatment of patients developing posttransplant neoplasias [9].

The mechanism of antitumor activity is also correlated to the upregulation of adhesion molecules and to a switch to less invasive phenotype of tumoral cells. Moreover, the inhibition of angiogenesis is due to the reduction of vascular endothelial growth factor (VEGF) production and decreased endothelial sensitivity to such growth factor [12–14].

Moreover, mTOR-I may reduce the incidence of several comorbidities associated with transplantation and chronic kidney disease including atherosclerosis [15] and complications correlated to polycystic kidney disease [16, 17].

Although the clinical utility of this drug category is clear, as other immunosuppressive drugs, mTOR-I may induce the development of several adverse effects (Table 1) that need to be early recognized and treated to avoid severe illness in renal transplant patients.

However, although the majority of the mTOR-I clinical trials have been performed in renal transplant patients using SRL, it seems reasonable that EVR may induce similar adverse effects. Sánchez-Fructuoso et al. have recently reported no difference in the rate of drug discontinuation for adverse effects between EVR- and SRL-treated patients [18]. In addition, it is conceivable that most results from initial clinical trials using SRL can not be compared with those obtained by more recent studies using EVR mainly because of the different dosages used, dissimilar trough levels reached and drug combinations proposed. Nevertheless, randomized clinical trials are necessary to better address this important clinical research topic.

In this review we focus our attention only on the main nonrenal adverse effects/toxicities occurring in renal transplant patients treated with both mTOR inhibitors.

## 2. Pulmonary Toxicity

Pulmonary adverse effects/toxicities are highly frequent in renal transplant recipients treated with mTOR-I. Numerous clinical studies have reported a frequency of this complication of 2–11% with the onset of symptoms between 1 and 51 months after the initiation of SRL or EVR therapy [19–22].

Mtor-I-associated pneumonitis has heterogeneous clinical manifestations and may begin with fever, fatigue, coughing and dyspnoea, and nonspecific signs and symptoms, which do not facilitate diagnosis [23].

Several distinct types of pulmonary damage have been recognized, including lymphocytic interstitial pneumonitis, lymphocytic alveolitis, bronchiolitis obliterans with organizing pneumonia, focal pulmonary fibrosis, or a combination thereof [24, 25]. Diffuse alveolar hemorrhage has been reported following the use of both SRL and EVR [26, 27].

The etiopathogenic mechanism of mTOR-I-associated pulmonary toxicity is still unclear, and several in vivo and in vitro studies have tried to define the biological machinery associated with this heterogeneous clinical condition.

A cell-mediated autoimmune response may have a pivotal role when cryptic pulmonary antigens are exposed, and this

| Adverse events                        | Rate of occurrence (%) | References                          |
|---------------------------------------|------------------------|-------------------------------------|
| Pulmonary toxicity                    | 2–11                   | [20, 21, 24, 33]                     |
| Hematopoietic adverse effects         |                        |                                     |
| Anemia                                | 13–58                  | [6, 36, 44–47, 50, 56, 57, 70, 72, 135, 147] |
| Leukopenia                            | 5–39                   | [6, 45, 46, 56, 66, 117, 121, 147]    |
| Thrombocytopenia                      | 4–45                   | [6, 45–47, 56, 66, 70, 117, 118, 121, 122, 147] |
| Metabolic disorders                   |                        |                                     |
| Hyperlipidemia                        | 8–87                   | [6, 45–47, 57, 66, 70–72, 115, 117, 118, 121, 135, 147] |
| Posttransplantation diabetes          | 3–33                   | [56, 70, 72, 78, 80, 115, 121, 138, 147] |
| Hypophosphatemia                      | 15–20                  | [45, 46, 57]                         |
| Lymphedema                            | <5                     | [99–102]                            |
| Cardiovascular disease                | 1–6                    | [80, 100, 117, 122, 124, 128]        |
| Hypertension                          | 8–58                   | [46, 57, 70, 72, 115, 117, 121, 122, 135] |
| Cutaneous adverse effects             |                        |                                     |
| Acne, folliculitis                    | 9–25                   | [6, 57, 70, 116–118, 135, 147]       |
| Stomatitis and mucous membrane disorders | 9–64               | [6, 118, 138, 147]                   |
| Edema                                 | 2–70                   | [6, 56, 57, 70, 121, 122, 135, 147]  |
| Nail and hair pathologies             | 74                     | [116]                               |
| Gonadal complications                | <5                     | [123–126]                           |
| Surgical wound complication           | 2–20                   | [56, 70, 72, 133–136]               |
| Infections                            | 2–60                   | [6, 72, 117, 122, 136]              |
| Gastrointestinal complication         | 2–51                   | [6, 46, 47, 56, 57, 70, 72, 117, 118, 121, 135, 147] |
causes lymphocytic alveolitis and interstitial pneumonitis. T-cell-mediated, delayed-type hypersensitivity may be another pathogenic mechanism [19]. Additionally, Ussavarungsiet al. have recently reported that SRL may induce granulomatous interstitial inflammation which suggests a role of T-cell-mediated hypersensitivity reaction to circulating antigens or immune complexes in the lungs [28]. T-cell lymphocytes produce IL-2 and IFN-gamma which stimulate alveolar macrophages and also produce TNF-alpha and IL-1. Activated macrophages secrete several chemokines such as monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein 1 alpha (MIP-1α) and transform into epithelioid cells and multinucleated cells contributing to cellular infiltration and granuloma formation [29]. Additionally, the existence of a dose-dependent effect was strongly suggested because this disease has been observed particularly in kidney transplant patients receiving high doses of SRL.

Therefore, to assume a possible correlation between pulmonary disease and mTOR-I administration, patients should present the following conditions:

1. exposure to mTOR-I preceding the onset of pulmonary symptoms;
2. exclusion of infection or alternative pulmonary disease, including toxicity due to other drugs, such as azathioprine, beta-blockers, fibrates, sulfamethoxazole, and trimethoprim;
3. resolution after mTOR-I discontinuation or minimization;
4. presentation of a lymphocytic alveolar cellular profile and pathological findings, although nonspecific, consistent with drug-induced pulmonary toxicity.

Then, to achieve a correct diagnosis, radiographic tests, computer tomography (CT) and bronchoalveolar lavage (BAL), even whether often unspecific, are extremely useful. CT images generally describe ground glass opacities and/or peripheral interstitial infiltrates, while BAL generally shows an increased number of CD4+ cells with mast cells and eosinophils [19]. It is unquestionable that, when possible, BAL should be performed to rule out infectious processes in these immunocompromised patients. Then, pulmonary function tests, demonstrating a reduction of the diffusing capacity of carbon monoxide, are less helpful, with this condition being in overlap with several other clinical features [30, 31].

In most cases, it is also necessary to early perform a lung biopsy. Usually, the lung biopsy pattern may include several histological features such as the intra-alveolar nonnecrotizing epithelioid granuloma, lymphocytic interstitial inflammation, and a focal pattern of organizing pneumonia [32].

The treatment of these pulmonary forms is variable, and it needs a multidisciplinary approach (e.g., pneumologists, infectiologists, and nephrologists) and a combined use of several drugs (e.g., antibiotics, corticosteroids, and immunosuppressive drugs). Nevertheless, as reported by Weiner et al., the treatment of choice of these complications results generally in drug withdrawal [33, 34]. However, in some cases, mTOR-I dose reduction could be sufficient to control symptoms and avoid disease progression/complication. As described by White et al. the same strategies have been adopted in patients affected by advanced renal cell carcinoma chronically treated with EVR [30]. Additionally, a published overview of cases of mTOR inhibitor-related noninfectious pneumonitis in liver transplant recipients (104 treated with SRL and 9 with EVR) confirms this therapeutic strategy. In fact it was reported that, after diagnosis of mTOR-I pulmonary adverse effects, SRL was withdrawn in 87/104 patients, with complete resolution in 82 patients, partial resolution in 1 patient, and 4 deaths. Of the 13/104 patients who continued SRL at a reduced dose, 8 showed complete resolution and the remaining 5 either had persistent symptoms or relapsed. All five patients had complete resolution on drug discontinuation. Among the nine patients treated by EVR, drug was withdrawn in eight patients and continued at a reduced dose in one patient. All experienced complete recovery [35].

Concerning corticosteroids, it remains unclear whether these drugs may be useful to treat mTOR-I-related pulmonary complications [31]. No studies have adequately analyzed the effect of additional/different therapies for the treatment of pulmonary adverse effects/toxicities occurring in renal transplant recipients.

Therefore, in conclusion, all clinicians in charge of transplanted patients should be aware of this new entity of mTOR-I-associated pneumonitis as an alternative to the diagnosis of an opportunistic infection. Indeed, discontinuation or dose reduction of mTOR-I led in most of the cases to the complete and lasting resolution of symptoms.

3. Hematopoietic Adverse Effects

Hematopoietic adverse effects and bone marrow toxicity often occur after renal transplantation in patients undergoing mTOR inhibition. In particular, mTOR-I-treated patients develop anemia, leukopenia, and thrombocytopenia [36, 37].

3.1. Anemia. Anemia is common after kidney transplantation and has been recognized as a late complication of transplantation [38, 39]. It has been linked to multiple factors including poor allograft function, acute and chronic rejection, iron deficiency, viral infections, hemolytic uremic syndrome, treatment with angiotensin converting-enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) and immunosuppressive drugs [40–43].

Initial phases 1 and 2 dose escalation studies found a slower recovery of postoperative hemoglobin (Hb) levels in SRL-Cyclosporin A (CsA)/prednisone-treated compared with CsA/prednisone-treated renal transplant recipients [44]. Groth et al. reported an approximately 35% incidence of early posttransplant anemia in SRL-treated patients versus 25% in a CsA-treated group [45]. Kreis et al. observed a 43% incidence of anemia with SRL compared with 32% in the CsA arm in studies in which both treatment arms received either azathioprine or mycophenolate mofetil (MMF) [46].

A dose relationship between SRL and anemia development was documented in phase 3 trials comparing SRL 2mg/day with SRL 5mg/day administered along with CsA and corticosteroids (24 versus 35%, resp.) [46]. A second
The success of EPO-stimulating agents (ESAs) in increasing hemoglobin levels may be related to the cause of anemia and clinical reasons for anemia correction [38, 39]. The data suggest that ESA treatment soon after transplantation shortens the time of hemoglobin correction [60, 61]. Then, iron repletion is important, as even patients with suboptimal erythropoietin levels can correct anemia with adequate iron. Iron deficiency is common in the peritransplant period and treatment decreases the incidence of anemia at six months [62, 63].

3.2. Leukopenia and Thrombocytopenia. Since the early clinical trials with SRL in transplantation in 1996, it emerged that leukopenia and thrombocytopenia were amongst the most common adverse effects of the mTOR-I. These adverse effects were the most likely reasons for the intervention with mTOR-I to be terminated [44, 45, 64]. During the first 2 months of treatment, dose-dependent thrombocytopenia and leukopenia may occur in approximately 20% of renal transplant recipients [65].

Groth et al. reported in a randomized multicentre study [45] including first cadaveric renal allograft recipients randomized to CsA (n = 42) or SRL (n = 41) in association with corticosteroids and azathioprine that thrombocytopenia and leucopenia were striking adverse effects of SRL. However, these abnormalities improved 2 months after transplantation when the SRL target trough level was lowered from 30 to 15 ng/mL.

In another study from 14 European centres including 78 first cadaveric renal allograft recipients randomized to receive SRL (n = 40) or CsA (n = 38), a significant higher rate of thrombocytopenia has been reported in the SRL-treated group of patients compared to CNI-treated control (45% versus 8%) [46]. All patients received corticosteroids and MMF 2 g/day. SRL doses were adjusted to achieve steady-state trough levels of approximately 30 ng/mL for 2 months and 15 ng/mL thereafter.

Also EVR has been associated with both leucopenia and thrombocytopenia. As reported by Kovarik et al. leukocytopenia occurred in 11–19% of patients, while the incidence of thrombocytopenia was 10–17% of patients chronically treated with EVR [66].

One hypothesis to explain the myelosuppressive effects is based on in vitro findings that mTOR-I potentiate platelets destruction via agonist-induced aggregation. mTOR-I-treated platelets display increased sensitivity to adenosine diphosphate and/or thrombin receptor agonist peptide, resulting in augmented platelet aggregation and granule secretion [67]. An alternate hypothesis is that the myelosuppressive property of SRL is due to the inhibition of the signal transduction via the gp130 [beta] chain shared by a variety of cytokine receptors, including interleukin-II [68], granulocyte colony stimulation factor, and erythropoietin, which stimulate the production of platelets, leukocytes, and erythrocytes, respectively [69].

Drug-induced thrombocytopenia and/or leukopenia are generally self-limited toxicities. Only 7% of patients require SRL dose reduction and 4% temporary drug withdrawal. No patient requires permanent discontinuation of SRL therapy.
When dose reduction is necessary, amelioration of the toxic effects are evident within 24 hr, although up to 50 days are required for full recovery in a few patients [65].

4. Metabolic Disorders

The most common metabolic disorders following mTOR-I treatment are associated with a severe deregulation of the lipid and glucidic metabolism. Prevention, early recognition, and treatment of these complications may have a significant impact on long-term survival of these patients.

4.1. Hyperlipidemia. Dyslipidemia is a major risk factor for posttransplant cardiovascular-related morbidity and mortality [69].

Several papers have reported that mTOR-I are well-recognized major causes of posttransplantation hyperlipidemia. They increase high-density lipoproteins (HDL), low-density lipoproteins (LDL), cholesterol, and triglycerides in approximately 40 to 75% of patients who receive this therapy [4, 70–72]. In the same way the upregulation of adipocyte fatty acid-binding protein (aP2) expressed in macrophages and monocytes plays a key role in the increased accumulation of triglycerides [73].

The mTOR-I-induced dyslipidemia constitutes a critical clinical problem because the annual risk of a cardiovascular event is almost 50-fold greater for a renal transplant patient than for the general population, and these events account for over one-third of all deaths [74].

A study of Morisset et al. observed that cholesterol and triglyceride levels increase after 2–4 weeks of initiation of therapy, and this alteration reverted to near-baseline levels within 8 weeks after discontinuation of treatment. This demonstrated that hyperlipidemia is reversible and dose dependent [75].

The 3-Hydroxy-3-methyl coenzyme A (HMG-CoA) inhibitors (statins) alone or in combination with a second-line agent remain the main therapeutic option for mTOR-I-induced hyperlipidemia [76].

4.2. Posttransplantation Diabetes. Posttransplantation diabetes is a relatively frequent and unfortunate complication in patients carrying renal allografts [77]. All available information regarding potentially modifiable factors associated with or leading to diabetes should be part of a thoughtful decision-making process regarding the optimal maintenance of immunosuppression.

To date, only a few clinical studies have suggested that SRL and its analogues are associated with hyperglycemia [78–81].

The mechanisms by which SRL may cause new-onset diabetes (NOD) are not clearly defined. SRL acts on the mTOR, a serine/threonine kinase that integrates signals from various nutrients and growth factors to regulate protein translation through a variety of downstream effectors. Physiologic conditions such as hyperinsulinemia promote serine/threonine phosphorylation of insulin receptor substrate proteins that inhibits their function and promotes their degradation. Overactivation of mTOR/S6K cascade would exert a significant negative effect on the activity of downstream components of the insulin/PI3-K pathway, such as AKT, leading to insulin resistance [82, 83]. Inhibitors of mTOR would therefore be expected to prevent development of insulin resistance through this mechanism.

Additionally, Di Paolo et al. [82] studied 30 patients treated with long-term SRL and reported an unexpected impairment of insulin receptor substrate signaling and AKT activation, a finding that could help to explain deterioration of glucose metabolism in SRL-treated patients.

Other mechanisms that have been proposed for the induction of hyperglycemia by SRL include ectopic triglyceride deposition leading to insulin resistance [84, 85], impairment of insulin-mediated suppression of hepatic glucose production, or a direct toxic effect on pancreatic β cells [86, 87].

Another interesting hypothesis is that mTOR is involved in insulin signaling, and its inhibition may impede insulin-related gene transcription and expression, including glucose transporters. In particular, SRL abrogated the insulin-mediated increase in GLUT1 protein synthesis through partial inhibition of GLUT1 mRNA translation and partial inhibition of the rise in GLUT1 mRNA, resulting in the failure of insulin to stimulate glucose uptake. Similarly, mTOR is an inducer of ribosomal S6 kinase (S6K), and SRL blocks S6K activation or induces S6K inactivation through inhibition of T389 phosphorylation interfering with the transcript of insulin. This action may impact blood sugar levels [88].

Currently, it is considered that patients with an A1C assay ≥6.5% should start on glucose-lowering agents. As for type 2 diabetes, a stepwise approach should be adopted. The first step includes hygiene-dietetic recommendations (weight control, diet, and exercise). The second step is the initiation of an oral agent in monotherapy. The choice of the drug should take into account the patient-specific factors, graft function (some drugs or active metabolites are eliminated by the kidney), specific side effects, and potential pharmacokinetic interactions with immunosuppressive drugs (mainly interaction with CNI or mTOR-I through metabolism mediated by cytochrome P450, family 3, subfamily A, polypeptide 4/5 [CYP3A4/5]). The third step is a combination of oral agents with different mechanisms of actions. Combination therapy has not been investigated in kidney allograft recipients. The last step is the initiation of insulin with or without oral agents. If the target for glucose control is not achieved within 2–4 months, lifestyle interventions should be reassessed and patients should move to the next step [77].

About the immunosuppressive management of patients undergoing mTOR-I-related posttransplantation diabetes, there are still not well-defined guidelines, and although the switch to cyclosporine might be considered in selected patients, at the state of the art, no randomized clinical trial has been performed to better address this important point.

Teutonico et al. then reported that the discontinuation of CNIs and their replacement by SRL fails to ameliorate the glycometabolic profile of kidney transplant recipients. Rather, it is associated with a worsening of insulin resistance and an inappropriately low insulin response [79].

Unfortunately, experimental and clinical data on EVR are more scant.
4.3. Metabolic Syndrome. The concept of metabolic syndrome was first described by Reaven [89] as a combination of central obesity, dyslipidemia, hypertension, and fasting hyperglycemia, all thought to be based on insulin resistance and inflammation as the common pathophysiologic disturbances. In the general population, the presence of metabolic syndrome is associated with a risk for overt diabetes and cardiovascular diseases [90–92]. In addition, metabolic syndrome has been associated with proteinuria and reduced GFR, suggesting a link to chronic kidney disease [93, 94]. To the extent that diabetes (i.e., new-onset diabetes after transplantation), cardiovascular disease, and proteinuria are common complications of kidney transplantation, the role of metabolic syndrome in kidney transplantation recently has attracted a great deal of interest. Finally, the pathophysiology of the syndrome observed in the general population is dramatically altered by the effects of immunosuppressive medications in kidney transplant recipients. MTOR-I may have a primary effect [95].

5. Hypophosphatemia

A reduction in phosphate levels is an important toxicity of mTOR-I, therapy but the exact mechanism of this effect is not known. Symptoms of hypophosphatemia, including fatigue and weakness, occur when plasma phosphate concentration is <2 mg/dL [96], but when the levels drop to <1 mg/dL, serious complications can take place including confusion, weakness, myocardial dysfunction, and rhabdomyolysis [97].

Oral supplementation or the increment of phosphate intake from diet may be adequate for most patients.

6. Lymphedema

A study of Langer and Kahanshow that up to 38% of patients treated with cyclosporine and prednisone in association with SRL may present lymphoceles [98]. Lymphedema is a relatively rare adverse effect of mTOR-I therapy [99–102], but the underlying biological/physiological mechanism is not completely clarified.

Aboujaoude et al. have hypothesized that the lymphedema could be strongly associated with the enhanced lymph flow and the lymphatic disruption secondary to the surgical procedures, together with the well-known increased vascular permeability and vasodilation caused by SRL [103].

Moreover Huber et al. showed an antilymphangiogenic activity of mTOR-I which is the common denominator in the pathophysiology of edematous states. In particular they reported that rapamycin administration impairs downstream signaling of VEGF-A through inhibition of the mTOR/p70S6K pathway in lymphatic endothelial cells (LECs) and also interferes with the intracellular pathway activation of LEC by VEGF-C, the main initiator of lymphangiogenesis. Interestingly this antilymphangiogenic activity is not restricted to a specific mTOR-I; rather it is a general phenomenon of mTOR inhibition [104].

Before establishing the diagnosis of lymphatic disease caused by mTOR-I, it is necessary to rule out other potential causes such as neoplasia, infection, venous obstruction, and genetic predisposition. A chest radiography, CT, or ultrasound study and laboratory tests can help in the differential diagnosis.

Reduction or discontinuation of the immunosuppressive drug therapy is, at the state of the art, the only worthy strategy in patients with lymphedema.

7. Cardiovascular Disease

The renal transplant population is highly vulnerable to premature CVD, the major cause of death with a functioning graft [105]. The risk of occurrence of a cardiovascular event in renal transplant patients treated with mTOR-I could be related to hypercholesterolemia, hypertriglyceridemia, and new-onset diabetes. However, to the best of our knowledge, at the state of the art, no reports (including the most important clinical trials) have strongly demonstrated that the presence of CV risk factors actually translates into an increased incidence of CV events or CV diseases.

However, some in vitro experiments have also reported a prooxidant induced by mTOR-I whose effects may decrease NO availability [106–111].

This result is in line with some recent evidence reported by international cardiovascular research groups suggesting that SRL causes marked vascular dysfunction and nitrate resistance after continuous treatment for 7 days in animal model. This impaired vasorelaxation may, in part, be induced by upregulated mitochondrial superoxide release as well as by an upregulation of NADPH oxidase-driven superoxide production. Both processes could contribute to endothelial dysfunction observed after coronary vascular interventions with sirolimus-coated stents [111].

Another debated adverse effect related to mTOR-I is hypertension. As underlined by Reis et al. mTOR-I, similarly to CNI, have hypertensive effects. However, while CNI significantly promotes tachycardia and oxidative stress, mTOR-I seem to mainly interfere with lipid profile, hemorheology, and serotonin (5-HT) levels, without the same influence on catecholamine contents and lipid peroxidation. Thus, the cardiovascular disturbances underlying arterial hypertension development might be associated with distinct molecular/ cellular signatures hypothetically explained by differences in the mechanism of action of immunosuppressants [112].

On the contrary, Joannidès et al. [113] have recently demonstrated that a CsA-free regimen based on SRL reduces aortic stiffness, plasma endothelin-1, and oxidative stress in renal recipients suggesting a protective effect on the arterial wall that may be translated into cardiovascular risk reduction. This study was in line with others demonstrating a lower hypertension development in mTOR-I-treated compared to CNI inhibitors-treated patients [114, 115].

However, based on contradictory research reports, it is unquestionable that these data are insufficient to define the mTOR-I systemic cardiovascular influence and to draw definitive clinical conclusions. Therefore, additional studies are necessary to evaluate short- and long-term CV effects of mTOR-I treatment in renal transplant patients.
8. Cutaneous Adverse Effects

The clinical side effects of mTOR-I in the field of dermatology are edema, acne, epistaxis, aphthous ulceration, and vasculitis. Mahé et al. have performed a cross-sectional study in renal transplant recipients receiving SRL which underwent a dermatological examination. The main cutaneous adverse events they observed were infection, edema, mucous membrane pathologies, and nail disorders [116].

8.1. Acne. Acne is reported in 15% to 25% of organ transplant recipients treated with SRL [117, 118]. Mahé et al. have reported skin eruptions resembling acne, mainly located on the face and trunk, in 46% of evaluated patients. Moreover the male predominance of these acne-like eruptions suggests that this side effect is hormone dependent [116].

8.2. Mucous Membrane Disorders. One of the most common side effects reported in clinical trials of mTOR-I has been mucositis, probably because of the direct toxic effect of these drugs on oral and nasal mucous membranes. Numerous clinical trials have reported aphthous ulcers or oral ulcerations [47, 119]. Frequently they are confined to the soft mucosa of the mouth and very common on the tongue and lips. Mouth ulcers usually occur just after the introduction of SRL treatment but most of the time are transient. However if persistent, these painful and debilitating lesions lead to either dose reduction or discontinuation of mTOR-I in a significant number of patients [120].

Topical steroid, iodine, or topical analgesic may be used to reduce pain and to promote disappearance of the ulcer. If symptoms persist, mTOR-I should be discontinued and possibly restarted at a lower dose after resolution of symptoms. Anyway it is important to educate patients to maintain good oral hygiene and inform patients about this side effect. Finally, it is important to perform a careful oral examination during the routine followup.

8.3. Edema. Chronic edema has been reported in 8% to 62% of renal transplant recipients receiving SRL treatment [103, 121, 122].

Mahé et al. have found chronic edemas (lasting more than 1 month, resistant to diuretics and without local, renal, or cardiac causes) in 55% of evaluated renal transplant recipients. Edemas affected primary lower limbs and are soft and noninflammatory. Angioedema (acute subcutaneous edema), found in 15% of patients, developed within a few hours and disappeared in less than 4 days. They were nonpruritic, nonerythematous, and localized mainly on the face, with oral cavity involvement [116].

8.4. Nail and Hair Pathologies. Nail abnormalities associated with SRL treatment include fragile and thin nails, longitudinal ridging, distal onycholysis, and erythema.

Skin and scalp hair abnormalities comprised mild alopecia or hypertrichosis of the face [116]. In most cases these adverse events were not serious, but in 12% of patients it has been necessary to withdraw the therapy.

9. Gonadal Impact

In the last years several studies have emphasized the impact of SRL on male gonadal function. In detail these studies have focused on sex hormones production, erectile function, and fertility. Regarding the balance on sex hormones production, three studies have revealed significantly lower testosterone levels and a significant increase in gonadotrophic hormones (FSH and LH) in patients treated with SRL [123, 124]. As regard the impact of SRL on sperm, a significant reduction in total sperm count and fathered pregnancy rate in patients who receive SRL compared to patients with SRL-free regimen has been shown [125, 126]. The molecular mechanisms by which mTOR-I induces a decrease in testosterone level and sperm impairment still remain partly unknown. In an animal model Feng et al. found that SRL plays a central inhibitory role on a stem cell factor (SCF)/c-kit-dependant process in spermatogonial proliferation via the PI3-K/AKT/p70S6K pathway [127].

10. Bone Diseases

Posttransplant renal osteopathy is a clinical posttransplant complication associated with morbidity and mortality due to the increased frequency of bone fractures compared with general population [128]. Osteopenia, osteoporosis, and osteonecrosis represent the most common complications related to renal transplant [129]. In a cross-sectional study, osteoporosis was observed in 40% and bone fracture in 44% of renal transplant recipients evaluated 8 years after transplantation [130]. Certainly, steroid treatment represents the more important pathogenic factor of osteopenic-osteoporosis syndrome in these patients. In experimental study on rats, SRL increased remodeling and growth retardation of bone but did not produce bone loss [131].

Contrarily, EVR directly inhibits bone resorption controlled by osteoclasts, and then it should be used in patients with concomitants bone disease [132].

11. Surgical Wound Complication

SRL treatment has been reported to be associated with a greater incidence of wound-healing problems than other maintenance immunosuppressive agents [133–136]. This effect is likely related to its ability to impair signal transduction of fibroblast and endothelial growth factors [137].

Knight et al. have evaluated the risk factors for wound complications (infection, lymphocoele, and/or incisional hernia) in renal transplant recipients with de novo SRL treatment. They found that one-third of recipients suffered at least one wound complication after one-year followup. The independent risk factors for the development of these complications are age, obesity, Caucasian race, and high dose of SRL in the first few days after transplantation. They concluded with useful recommendations including the avoidance of a large loading dose of SRL and delay the introduction of this agent for several days particularly for Caucasian, older aged recipients, and patients with a BMI > 30 [138].
12. Infections

The severe infections are frequent cause of mTOR-I discontinuation [18, 139, 140] and one of the leading causes of death in renal transplant recipients [141, 142]. In particular, several biomolecular studies have shown that SRL is able to inhibit interleukin-12-induced proliferation of activated T lymphocytes [143] and IFN-γ production of the lymphocytes. Both cytokines are known to be critical in protective immunity to intracellular bacteria (e.g., mycobacterium) [144].

Literature evidence, then, suggests that both SRL- and EVR-based regimens are associated with low CMV infection rate in comparison with other immunosuppressive regimens [141, 145]. The mechanism underlying the apparent beneficial effect of SRL in reducing the risk of CMV-related infection and invasive disease in this patients’ population remains speculative but may relate to the effect of mTOR inhibition on CMV replication. As an obligate intracellular organism, CMV must utilize the intrinsic metabolic pathways of the host cell to direct the synthesis of proteins that are essential to its replication. Since mTOR serves as a key regulator of cellular metabolism, its inhibition by SRL may, in turn, inhibit CMV replication. Experimental models of CMV infection suggest that SRL impairs, but does not entirely prevent, CMV replication, so other mechanisms are likely involved as well [146].

However, further investigations should be undertaken to better analyze the biological/biomolecular machinery associated with this condition, and randomized clinical trials with homogeneous antiviral prophylaxis, standardized definitions, and adequate statistical power need to be performed to confirm these clinical observations.

13. Others

Other complications, reported in approximately 15–20%, include gastrointestinal side effects (e.g., diarrhea, vomiting, and anorexia) [147]. Gastrointestinal leukocytoclastic vasculitis is a rare adverse effect reported in a few cases of use of SRL. It is characterized by diffuse mucosal thickening of the antrum, duodenum, and jejunum. Esophagastroduodenoscopy revealed erythema, swelling, and white plaques in the antrum, asymmetrical pylorus, and granular swelling of the third portion of the duodenum [148]. In presence of these complications, drug discontinuation is encouraged.

Fatigue, alterations in taste, and asthenia are other common toxicities. These symptoms were usually manageable with a reduction in the drug dose [149].

Conflict of Interests

The authors have no conflict of interests to disclosure.

References

[1] E. K. Geissler, H. J. Schlitt, and G. Thomas, “mTOR, cancer and transplantation,” American Journal of Transplantation, vol. 8, no. 11, pp. 2212–2218, 2008.

[2] J. R. Chapman, H. Valantine, J. Albanell et al., “Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy,” Transplantation Proceedings, vol. 39, no. 10, pp. 2937–2950, 2007.

[3] S. N. Sehgal, “Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression,” Clinical Biochemistry, vol. 31, no. 5, pp. 335–340, 1998.

[4] C. Morath, W. Arns, V. Schwenger et al., “Sirolimus in renal transplantation,” Nephrology, Dialysis, Transplantation, vol. 22, supplement 8, pp. vii61–vi65, 2007.

[5] E. Paoletti, E. Ratto, D. Bellino et al., “Effect of early conversion from CNI to sirolimus on outcomes in kidney transplant recipients with allograft dysfunction,” Journal of Nephrology, vol. 25, no. 5, pp. 709–718, 2012.

[6] F. P. Schena, M. D. Pascoe, J. Alberu et al., “Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial,” Transplantation, vol. 87, no. 2, pp. 233–242, 2009.

[7] N. Pallet and C. Legendre, “Adverse events associated with mTOR inhibitors,” Expert Opinion on Drug Safety, vol. 12, no. 2, pp. 177–186, 2012.

[8] G. Stallone, B. Infante, G. Grandaliano, and L. Gesualdo, “Management of side effects of sirolimus therapy,” Transplantation, vol. 87, no. 8, pp. S23–26, 2009.

[9] S. A. Wander, B. T. Hennessy, and J. M. Slingerland, “Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy,” Journal of Clinical Investigation, vol. 121, no. 4, pp. 1231–1241, 2011.

[10] P. Cen and R. J. Amato, “Treatment of advanced pancreatic neuroendocrine tumors: potential role of everolimus,” OncoTargets and Therapy, vol. 5, pp. 217–224, 2012.

[11] D. J. Kwiatkowski, “Tubercous sclerosis: from tubers to mTOR,” Annals of Human Genetics, vol. 67, no. 1, pp. 87–96, 2003.

[12] G. Stallone, A. Schena, B. Infante et al., “Sirolimus for Kaposi’s sarcoma in renal–transplant recipients,” The New England Journal of Medicine, vol. 352, no. 13, pp. 1317–1323, 2005.

[13] X. B. Trinh, W. A. A. Tjalma, P. B. Vermeulen et al., “The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer,” British Journal of Cancer, vol. 100, no. 6, pp. 971–978, 2009.

[14] S. H. Advani, “Targeting mTOR pathway: a new concept in cancer therapy,” Indian Journal of Medical and Paediatric Oncology, vol. 31, no. 4, pp. 132–156, 2010.

[15] V. Andrés, C. Castro, and J. M. Campistol, “Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients,” Nephrology Dialysis Transplantation, vol. 21, no. 3, pp. iii14–iii17, 2006.

[16] J. J. Grantham, W. M. Bennett, and R. D. Perrone, “mTOR inhibitors and autosomal dominant polycystic kidney disease,” The New England Journal of Medicine, vol. 364, no. 3, pp. 286–287, 2011.

[17] J. M. Shillingsford, C. P. Leamon, I. R. Vlahov et al., “Folate-conjugated rapamycin slows progression of polycystic kidney disease,” Journal of the American Society of Nephrology, vol. 23, no. 10, pp. 1674–1681, 2012.

[18] A. I. Sánchez-Fructuoso, J. C. Ruiz, I. Pérez-Flores, C. Gómez Alamillo, N. Calvo Romero, and M. Arias, “Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus,” Transplantation Proceedings, vol. 42, no. 8, pp. 3050–3052, 2010.
defining a therapeutic range,” *Transplantation*, vol. 73, no. 6, pp. 920–925, 2002.

[67] A. Babinska, M. S. Markell, M. O. Salifu, M. Akoad, Y. H. Ehrlich, and E. Kornecki, “Enhancement of human platelet aggregation and secretion induced by rapamycin,” *Nephrology Dialysis Transplantation*, vol. 13, no. 12, pp. 3153–3159, 1998.

[68] S. R. Paul, F. Bennett, J. A. Calvetti et al., “Molecular cloning of a cDNA encoding interleukin II, a stalk cell-derived lymphopoietic and hematopoietic cytokine,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 87, no. 19, pp. 7512–7516, 1990.

[69] V. F. J. Quesniaux, S. Wehrl, C. Steiner et al., “The immunosuppressant rapamycin blocks in vitro responses to hematopoietic cytokines and inhibits recovering but not steady-state hematopoiesis in vivo,” *Blood*, vol. 84, no. 5, pp. 1543–1552, 1994.

[70] S. M. Flechner, M. Glyda, S. Cockfield et al., “The ORION study: comparison of two sirolimus-based regimens versus tacrolimus and mycophenolate mofetil in de novo allograft recipients,” *American Journal of Transplantation*, vol. 11, no. 8, pp. 1633–1644, 2011.

[71] C. Brattström, H. Wilczek, G. Tydén, B. Böttiger, J. Säve, and C.-G. Groth, “Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin),” *Transplantation*, vol. 65, no. 9, pp. 1272–1274, 1998.

[72] H. Ekberg, C. Bernasconi, J. Nöldeke et al., “Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study,” *Nephrology Dialysis Transplantation*, vol. 25, no. 6, pp. 2004–2010, 2010.

[73] Q.-Y. Liu and P. Nambi, “Sirolimus upregulates aP2 expression in human monocytes and macrophages,” *Transplantation Proceedings*, vol. 36, no. 10, pp. 3229–3231, 2004.

[74] B. A. Kibard, “Cardiovascular risk reduction in renal transplantation: strategies for success,” *Minerva Urologica e Nefrologica*, vol. 54, no. 2, pp. 51–63, 2002.

[75] J. D. Morrisett, G. Abdel-Fattah, R. Hoogeveen et al., “Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients,” *Journal of Lipid Research*, vol. 43, no. 8, pp. 1170–1180, 2002.

[76] B. L. Kasiske, A. De Mattos, S. M. Flechner et al., “Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients,” *American Journal of Transplantation*, vol. 8, no. 7, pp. 1384–1392, 2008.

[77] L. Ghisdal, S. Van Laecke, M. J. Abramowicz, R. Vanholder, and D. Abramowicz, “New-onset diabetes after renal transplantation: risk assessment and management,” *Diabetes Care*, vol. 35, no. 1, pp. 181–188, 2012.

[78] J. Romagnoli, F. Citterio, G. Nanni et al., “Incidence of post-transplant diabetes mellitus in kidney transplant recipients immunosuppressed with sirolimus in combination with cyclosporine,” *Transplantation Proceedings*, vol. 38, no. 4, pp. 1034–1036, 2006.

[79] A. Teutonico, P. F. Schena, and S. Di Paolo, “Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus,” *Journal of the American Society of Nephrology*, vol. 16, no. 10, pp. 3128–3135, 2005.

[80] G. Ciancio, G. W. Burke, J. J. Gaynor et al., “A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (neoral)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year,” *Transplantation*, vol. 77, no. 2, pp. 252–258, 2004.

[81] E. Sulanc, J. T. Lane, S. E. Puumala, G. C. Groggel, L. E. Wrenshall, and R. B. Stevens, “New-onset diabetes after kidney
transplantation: an application of 2003 International Guidelines,” Transplantation, vol. 80, no. 7, pp. 945–952, 2005.

[82] S. Di Paolo, A. TeutonicO, D. Leogrande, C. Capobianco, and P. F. Schena, “Chronic inhibition of mammalian target of rapamycin signaling downregulates insulin receptor substrates 1 and 2 and AKT activation: a crossroad between cancer and diabetes?” Journal of the American Society of Nephrology, vol. 17, no. 8, pp. 2236–2244, 2006.

[83] N. Hay and N. Sonenberg, “Upstream and downstream of mTOR,” Genes and Development, vol. 18, no. 16, pp. 1926–1945, 2004.

[84] G. F. Lewis, A. Carpentier, K. Adeli, and A. Giacca, “Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes,” Endocrine Reviews, vol. 23, no. 2, pp. 201–229, 2002.

[85] S. D. Mittelman and R. N. Bergman, “Inhibition of lipolysis causes suppression of endogenous glucose production independent of changes in insulin,” American Journal of Physiology, vol. 279, no. 3, pp. E630–E637, 2000.

[86] C. T. Bussiere, J. R. T. Lakey, A. M. J. Shapiro, and G. S. Korbutt, “The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells,” Diabetologia, vol. 49, no. 10, pp. 2341–2349, 2006.

[87] G. Kwon, C. A. Marshall, H. Liu, K. L. Pappan, M. S. Remedi, and M. L. McDaniel, “Glucose-stimulated DNA synthesis through mammalian target of rapamycin (mTOR) is regulated and AKT activation: a crossroad between cancer and diabetes?” Journal of Biological Chemistry, vol. 281, no. 6, pp. 3261–3267, 2006.

[88] C. Taha, Z. Liu, J. Jin, H. Al-Hasani, N. Sonenberg, and A. Klip, “Opposite translational control of GLUT1 and GLUT4 glucose transporter mRNAs in response insulin. Role of mammalian target of rapamycin, protein kinase B, and phosphatidylinositol 3-kinase in GLUT1 mRNA translation,” Journal of Biological Chemistry, vol. 274, no. 46, pp. 33085–33091, 1999.

[89] G. M. Reaven, “Role of insulin resistance in human disease,” Diabetes, vol. 37, no. 12, pp. 1595–1607, 1988.

[90] M. Pyöräla, H. Miettinen, M. Laakso, and K. Pyöräla, “Plasma insulin and all-cause cardiovascular, and noncardiovascular mortality: the 22-year follow-up results of the Helsinki Police-Men Study,” Diabetes Care, vol. 23, no. 8, pp. 1097–1102, 2000.

[91] G. Schillaci, M. Pirro, G. Vaudo et al., “Prognostic value of the metabolic syndrome in essential hypertension,” Journal of the American College of Cardiology, vol. 43, no. 10, pp. 1817–1822, 2004.

[92] A. S. Gami, B. J. Witt, D. E. Howard et al., “Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies,” Journal of the American College of Cardiology, vol. 49, no. 4, pp. 403–414, 2007.

[93] J. Chen, P. Muntner, L. L. Hamm et al., “Insulin resistance and risk of chronic kidney disease in nondiabetic US adults,” Journal of the American Society of Nephrology, vol. 14, no. 2, pp. 469–477, 2003.

[94] S.-J. Pinto-Sietsma, G. Navis, W. M. T. Janssen, D. De Zeeuw, R. O. B. Gans, and P. E. De Jong, “A central body fat distribution is related to renal function impairment, even in lean subjects,” American Journal of Kidney Diseases, vol. 41, no. 4, pp. 733–741, 2003.

[95] D. E. Hricik, “Metabolic syndrome in kidney transplantation: management of risk factors,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 7, pp. 1781–1785, 2011.

[96] S. A. Soefje, A. Karnad, and A. J. Brenner, “Common toxicities of mammalian target of rapamycin inhibitors,” Targeted Oncology, vol. 6, no. 2, pp. 125–129, 2011.

[97] M. Levi, “Post-transplant hypophosphatemia,” Kidney International, vol. 59, no. 6, pp. 2377–2387, 2001.

[98] R. M. Langer and B. D. Kahan, “Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients,” Transplantation, vol. 74, no. 6, pp. 804–808, 2002.

[99] J. Romagnoli, F. Cittergio, G. Nanni, V. Tondolo, and M. Castagno, “Severe limb lymphedema in sirolimus-treated patients,” Transplantation Proceedings, vol. 37, no. 2, pp. 834–836, 2005.

[100] T. Al-Otaibi, N. Ahamed, M. R. N. Nampoory et al., “Lymphedema: an unusual complication of sirolimus therapy,” Transplantation Proceedings, vol. 39, no. 4, pp. 1207–1210, 2007.

[101] C. De Bartolomeis, A. Collini, B. Rumberger et al., “Generalized lymphedema in a sirolimus-treated renal transplant patient,” Clinical Transplantation, vol. 22, no. 2, pp. 254–257, 2008.

[102] A. Ersosy and N. Koca, “Everolimus-induced lymphedema in a renal transplant recipient: a case report,” Experimental and Clinical Transplantation, vol. 10, no. 3, pp. 296–298, 2012.

[103] W. Aboujaoude, M. L. Milgrom, and M. V. Govani, “Lymphedema associated with sirolimus in renal transplant recipients,” Transplantation, vol. 77, no. 7, pp. 1094–1096, 2004.

[104] S. Huber, C. J. Bruns, G. Schmid et al., “Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis,” Kidney International, vol. 71, no. 8, pp. 771–777, 2007.

[105] A. G. Jardine, R. S. Gaston, B. C. Fellstrom, and H. Holdaas, “Prevention of cardiovascular disease in adult recipients of kidney transplants,” The Lancet, vol. 378, no. 9800, pp. 1419–1427, 2011.

[106] A. Saurina, J. M. Campistol, S. Lario, F. Oppenheimer, and F. Diekmann, “Conversion from calcineurin inhibitors to sirolimus in kidney transplant patients reduces the urinary transforming growth factor-β1 concentration,” Transplantation Proceedings, vol. 39, no. 7, pp. 2138–2141, 2007.

[107] D. Ramzy, V. Rao, L. C. Tumiati et al., “Role of endothelin-1 and nitric oxide bioavailability in transplant-related vascular injury: comparative effects of rapamycin and cyclosporine,” Circulation, vol. 114, no. 1, pp. 1214–1219, 2006.

[108] S. Milliard, A. Silva, G. Blaise et al., “Rapamycin’s effect on vasomotion in the rat,” Transplantation Proceedings, vol. 30, no. 4, pp. 1036–1038, 1998.

[109] E. Raichlin, J.-H. Bae, Z. Khalpey et al., “Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation,” Circulation, vol. 116, no. 23, pp. 2726–2733, 2007.

[110] J. Steffel, R. A. Latini, A. Akhmedov et al., “Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design,” Circulation, vol. 112, pp. 2002–2011, 2005.

[111] A. Jabs, S. Gobel, P. Wenzel et al., “Sirolimus-induced lymphedema: an unusual complication of sirolimus therapy,” Transplantation Proceedings, vol. 37, no. 2, pp. 834–836, 2005.

[112] F. Reis, B. Parada, E. Teixeira de Lemos et al., “Hypertension induced by immunosuppressive drugs: a comparative analysis between sirolimus and cyclosporine,” Transplantation Proceedings, vol. 41, no. 3, pp. 868–873, 2009.
R. Joannidès, C. Monteil, B. H. De Ligny et al., "Immunosuppressant regimen based on sirolimus decreases aortic stiffness in renal transplant recipients in comparison to cyclosporine," American Journal of Transplantation, vol. 11, no. 11, pp. 2414–2422, 2011.

J. M. Morales, "Influence of the new immunosuppressive combinations on arterial hypertension after renal transplantation," Kidney International, Supplement, vol. 62, no. 82, pp. S81–S87, 2002.

C. Legendre, J. M. Campistol, J.-P. Squifflet, and J. T. Burke, "Cardiovascular risk factors of sirolimus compared with cyclosporine: early experience from two randomized trials in renal transplantation," Transplantation Proceedings, vol. 35, no. 3, pp. 1515–1533, 2003.

E. Mahé, E. Morelon, S. Lechaton et al., "Cutaneous adverse events in renal in renal transplant recipients receiving sirolimus-based therapy," Transplantation, vol. 79, no. 4, pp. 476–482, 2005.

B. D. Kahan, "Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study," The Lancet, vol. 356, no. 9225, pp. 194–202, 2000.

S. Reitamo, P. Spuls, M. Lahfa, A. Claudy, and C. E. M. Griffiths, "Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial," British Journal of Dermatology, vol. 145, no. 3, pp. 438–445, 2001.

T. van Gelder, C. G. Ter Meulen, R. Hené, W. Weimar, and A. Hoitsma, "Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil," Transplantation, vol. 75, no. 6, pp. 788–791, 2003.

L. Rostaing and N. Kamar, "mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?" Journal of Nephrology, vol. 23, no. 2, pp. 133–142, 2010.

B. D. Kahan, "Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation," Transplantation Proceedings, vol. 35, no. 3, pp. 375–515, 2003.

R. Oberbauer, H. Kreis, R. W. G. Johnson et al., "Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the rapamune maintenance regimen study," Transplantation, vol. 76, no. 2, pp. 364–370, 2003.

L. Fritsche, K. Budde, D. Dragun, G. Einecke, F. Diekmann, and H.-H. Neumayer, "Testosterone concentrations and sirolimus in male renal transplant patients," American Journal of Transplantation, vol. 4, no. 1, pp. 130–134, 2004.

S. Lee, M. Coco, S. M. Greenstein, R. S. Schechner, V. A. Tellis, and D. G. Glicklich, "The effect of sirolimus on sex hormone levels of male renal transplant recipients," Clinical Transplantation, vol. 19, no. 2, pp. 162–167, 2005.

L. Bererhi, M. Flamant, F. Martinez, A. Karras, E. Therving, and C. Legendre, "Rapamycin-induced oligospermia," Transplantation, vol. 76, no. 5, pp. 885–886, 2003.

J. Zuber, D. Anglicheau, C. Elie et al., "Sirolimus may reduce fertility in male renal transplant recipients," American Journal of Transplantation, vol. 8, no. 7, pp. 1471–1479, 2008.

L.-X. Feng, N. Ravindranath, and M. Dym, "Stem cell factor/c-kit up-regulates cyclin D3 and promotes cell cycle progression via the phosphoinositide 3-kinase/p70 S6 kinase pathway in spermatogonia," Journal of Biological Chemistry, vol. 275, no. 33, pp. 25572–25576, 2000.

A. Sessa, A. Esposito, G. D. Iavicoli et al., "Immunosuppressive agents and bone disease in renal transplant patients with hypercalcemia," Transplantation Proceedings, vol. 42, no. 4, pp. 1148–1155, 2010.

S. Bandini, "La patologia ossea nel paziente trapiantato renale," Giornale di Tecniche Nefrologiche & Dialitiche, vol. 19, no. 3–4, pp. 54, 2007.

S. Durieux, L. Mercadal, P. Orce et al., "Bone mineral density and fracture prevalence in long-term kidney graft recipients," Transplantation, vol. 74, no. 4, pp. 496–500, 2002.

H. P. Bryer, J. A. Isserow, E. C. Armstrong et al., "Azathioprine alone is bone sparing and does not alter cyclosporin A-induced osteopenia in the rat," Journal of Bone and Mineral Research, vol. 10, no. 1, pp. 132–138, 1995.

M. Kneissl, N.-H. Luong-Nguyen, M. Baptist et al., "Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts," Bone, vol. 35, no. 5, pp. 1144–1156, 2004.

J. E. Valente, D. Hricik, K. Weigel et al., "Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation," American Journal of Transplantation, vol. 3, no. 9, pp. 1128–1134, 2003.

P. G. Dean, W. J. Lund, T. S. Larson et al., "Wound-healing complication after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus," Transplantation, vol. 77, no. 10, pp. 1555–1561, 2004.

A. O. Gaber, B. D. Kahan, C. Van Buren, S. L. Schuman, J. Scarola, and J. F. Neylan, "Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized Trial," Transplantation, vol. 86, no. 9, pp. 1187–1195, 2008.

A. Srivastava, K. Muruganandham, P. B. Vinodh et al., "Postrenal transplant surgical complications with newer immunosuppressive drugs: mycophenolate mofetil vs. m-TOR inhibitors," International Urology and Nephrology, vol. 42, no. 2, pp. 279–284, 2010.

R. V. Nair, X. Huang, R. Shorthouse et al., "Antiproliferative effect of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliteratoric airway disease in vivo," Transplantation Proceedings, vol. 29, no. 1–2, pp. 614–615, 1997.

R. J. Knight, M. Villa, R. Laskey et al., "Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients," Clinical Transplantation, vol. 21, no. 4, pp. 460–465, 2007.

J. J. Snyder, A. K. Israni, Y. Peng, L. Zhang, T. A. Simon, and B. L. Kasiske, "Rates of first infection following kidney transplant in the United States," Kidney International, vol. 75, no. 3, pp. 317–326, 2009.

S. Sagedal, A. Hartmann, K. P. Nordal et al., "Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival," Kidney International, vol. 66, no. 1, pp. 329–337, 2004.

J. Fortun, P. Martin-Davila, J. Pascual et al., "Immunosuppressive therapy and infection after kidney transplantation," Transplant Infectious Disease, vol. 12, no. 5, pp. 397–405, 2010.

O. Thaunat, E. Morelon, M. Stern et al., "Mycobacterium xenopi pulmonary infection in two renal transplant recipients under sirolimus therapy," Transplant Infectious Disease, vol. 6, no. 4, pp. 179–182, 2004.
M. M. Bertagnolli, L. Yang, S. H. Herrmann, and R. L. Kirkman, “Evidence that rapamycin inhibits interleukin-12-induced proliferation of activated T lymphocytes,” Transplantation, vol. 58, no. 10, pp. 1091–1096, 1994.

D. A. Lammas, J.-L. Casanova, and D. S. Kumararatne, “Clinical consequences of defects in the IL-12-dependent interferon-gamma (IFN-γ) pathway,” Clinical and Experimental Immunology, vol. 121, no. 3, pp. 417–425, 2000.

B. Nashan, R. Gaston, V. Emery et al., “Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients,” Transplantation, vol. 93, no. 11, pp. 1075–1085, 2012.

R. A. Johnson, X. Wang, X.-L. Ma, S.-M. Huong, and E.-S. Huang, “Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling,” Journal of Virology, vol. 75, no. 13, pp. 6022–6032, 2001.

Y. Lebranchu, A. Thierry, O. Toupance et al., “Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study,” American Journal of Transplantation, vol. 9, no. 5, pp. 1115–1123, 2009.

S. Nagarajan, T. Friedrich, M. Garcia, N. Kambham, and M. M. Sarwal, “Gastrointestinal leukocytoclastic vasculitis: an adverse effect of sirolimus,” Pediatric Transplantation, vol. 9, no. 1, pp. 97–100, 2005.

G. Hudes, M. Carducci, P. Tomczak et al., “Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma,” The New England Journal of Medicine, vol. 356, no. 22, pp. 2271–2281, 2007.